This notwithstanding, our findings suggest that targeting the NF-κB pathway through GADD45β would provide an effective means to counter oncogenesis by reversing TME-mediated immunosuppression and, concurrently, inducing cancer-cell apoptosis, thereby providing dual therapeutic benefit (Fig. 1). Here, NFKB1 is linked to cancer.